Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.47 |
| ▸ | BRD2 | P25440 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309796 | 1.00 | BRD4 (0.47) | BRD4BRD2GAABRD3BRDT | |
| SCHEMBL309348 | 0.86 | MMP1 (0.45) | HSD11B1CA1CA2CA4CA9 | |
| SCHEMBL308001 | 0.86 | MMP1 (0.45) | HSD11B1CA1CA2CA4CA9 | |
| SCHEMBL1430398 | 0.82 | HSD11B1 (0.49) | HSD11B1 | |
| SCHEMBL2170723 | 0.82 | HSD11B1 (0.49) | HSD11B1 | |
| SCHEMBL1736316 | 0.72 | NR1H2 (0.52) | — | |
| SCHEMBL2439382 | 0.72 | MMP1 (0.59) | BRD4GAAHSD11B1MMP8 | |
| SCHEMBL16431471 | 0.72 | CA1 (0.57) | GAACA1CA2CA4CA9 | |
| SCHEMBL4582127 | 0.72 | FKBP1A (0.48) | BRD4GAA | |
| SCHEMBL5445749 | 0.72 | CA1 (0.48) | CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | BRD4 731/4885BRD2 319/4885GAA 3542/4885 |
| US-20100022555-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | BRD4 731/4885BRD2 319/4885GAA 3542/4885 |
| US-20110130379-A1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CACNA1B, CACNA1C, CACNB2 | BRD4 962/4885BRD2 467/4885GAA 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.